切换至 "中华医学电子期刊资源库"

中华肥胖与代谢病电子杂志 ›› 2021, Vol. 07 ›› Issue (02) : 99 -103. doi: 10.3877/cma.j.issn.2095-9605.2021.02.006

论著

达格列净联合二甲双胍对糖尿病合并冠心病患者氧化应激与糖脂代谢的影响
何航宇1,(), 廖伟亮1, 杨鸣宇1   
  1. 1. 525100 化州,广东省化州市人民医院心血管内科
  • 收稿日期:2021-01-11 出版日期:2021-05-30
  • 通信作者: 何航宇

Effects of dapagliflozin combined with metformin on oxidative stress and glucose and lipid metabolism in diabetic patients with coronary heart disease.

Hangyu He1,(), Weiliang Liao1, Mingyu Yang1   

  1. 1. Department of Cardiovascular Medicine, Huazhou People's Hospital , Guangdong Province, Huazhou 525100, China
  • Received:2021-01-11 Published:2021-05-30
  • Corresponding author: Hangyu He
引用本文:

何航宇, 廖伟亮, 杨鸣宇. 达格列净联合二甲双胍对糖尿病合并冠心病患者氧化应激与糖脂代谢的影响[J/OL]. 中华肥胖与代谢病电子杂志, 2021, 07(02): 99-103.

Hangyu He, Weiliang Liao, Mingyu Yang. Effects of dapagliflozin combined with metformin on oxidative stress and glucose and lipid metabolism in diabetic patients with coronary heart disease.[J/OL]. Chinese Journal of Obesity and Metabolic Diseases(Electronic Edition), 2021, 07(02): 99-103.

目的

探讨达格列净联合二甲双胍对糖尿病合并冠心病患者氧化应激与糖脂代谢的影响。

方法

选择2019年3月至2020年3月于广东省化州市人民医院心血管内科治疗的2型糖尿病合并冠心病患者共50例,随机分为处理组和对照组,每组25例,其中处理组采用达格列净联合二甲双胍干预血糖,对照组采用二甲双胍干预,比较两组患者干预前和干预6个月后的氧化应激指标包括血清丙二醛(MDA)、超氧化物歧化酶(SOD)、总抗氧化能力(TAC),脂代谢指标包括低密度脂蛋白(LDL-C)、高密度脂蛋白(HDL-C)、甘油三酯(TG)和总胆固醇(TC);糖代谢指标包括糖化血红蛋白(HbA1c)、空腹血糖(FPG)、餐后2 h血糖(2hPG)、空腹C肽。

结果

两组干预前的TAC、SOD、以及MDA水平对比差异无统计学意义(P>0.05),干预12周处理组的TAC和SOD水平均显著高于对照组,MDA水平显著低于对照组,差异具有统计学意义(P<0.05)。干预12周后处理组的TC、TG、LDL-C水平均显著低于对照组(P<0.05),处理组的HDL-C水平显著高于对照组(P<0.05),治疗12周后处理组FPG、2hPG和HbA1c水平显著低于对照组,而处理组的平均C肽水平显著高于对照组,差异具有统计学意义(P<0.05)。

结论

达格列净联合二甲双胍对糖尿病合并冠心病患者能显著提高机体抗氧化应激能力,改善患者的糖脂代谢。

Objective

To investigate the effect of dapagliflozin combined with metformin on oxidative stress and glucose and lipid metabolism in patients with diabetes and coronary heart disease.

Methods

A total of 50 patients with type 2 diabetes and coronary heart disease who were treated in department of Cardiovascular Medicine of Huazhou People's Hospital from March 2019 to March 2020 were selected and randomly divided into treatment group and control group, 25 cases in each group, of which dapagliflozin was used in the treatment group Combined with metformin to interfere with blood glucose, the control group was treated with metformin. The two groups of patients were compared before the intervention and 6 months after the intervention for oxidative stress indicators (TAC, SOD, MDA), lipid metabolism indicators (TG, TC, LDL-C, HDL-C) and glucose metabolism indicators (HbAlc, FPG, 2hPG, fasting C peptide).

Results

There was no significant difference in the levels of TAC, SOD, and MDA between the two groups before intervention (P>0.05). The TAC and SOD levels of the 12-week intervention group were significantly higher than those of the control group, and the MDA level was significantly lower than the control group , The difference was statistically significant (P<0.05). After 12 weeks of intervention, the levels of TC, TG, LDL-C in the treatment group were significantly lower than those in the control group (P<0.05), and the HDL-C levels in the treatment group were significantly higher than those in the control group (P<0.05). After 12 weeks of treatment, the FPG and 2hPG and HbA1c levels of the treatment group were significantly lower than those of the control group, while the average C peptide level of the treatment group was significantly higher than that of the control group, the difference was statistically significant (P<0.05).

Conclusions

Dapagliflozin combined with metformin can significantly improve the body's ability to resist oxidative stress and improve the glucose and lipid metabolism of patients with diabetes and coronary heart disease.

表1 两组患者的一般资料对比
表2 常规剂量组与低剂量组心功能指标比较分析(±sn=45)
表3 两组患者治疗前后TC、TG、LDL-C以及HDL-C水平对比
表4 两组患者治疗前后血糖、C肽以及HbA1c水平对比
[1]
Brown RE, Gupta N, Aronson R. Effect of dapagliflozin on glycemic control, weight, and blood pressure in patients with type 2 diabetes attending a specialist endocrinology practice in canada: a retrospective cohort analysis [J]. Diabetes Technology & Therapeutics, 2017, 19(11): 685-691.
[2]
Cai X, Yang W, Gao X, et al. The Association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis [J]. Obesity, 2018, 26(1): 70-80.
[3]
Cavender MA, Norhammar A, Birkeland KI, et al. SGLT-2 inhibitors and cardiovascular risk: an analysis of CVD-REAL [J]. Journal of the American College of Cardiology, 2018, 71(22): 2497-2506.
[4]
Fadini GP, Zatti G, Baldi I, et al. Use and effectiveness of dapagliflozin in routine clinical practice: an Italian multicentre retrospective study [J]. Diabetes, Obesity and Metabolism. 2018, 20(7): 1781-1786.
[5]
中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2017年版)[J]. 中华糖尿病杂志, 2018, 10(1): 4-67.
[6]
王斌, 李毅, 韩雅玲. 稳定性冠心病诊断与治疗指南 [J]. 中华心血管病杂志, 2018, 46(09): 680-694.
[7]
赛米·赛麦提, 买买提·依斯热依力, 艾克拜尔·艾力, 等. 肥胖与2型糖尿病关系的研究进展 [J/CD]. 中华肥胖与代谢病电子杂志, 2020, 6(2): 130-134.
[8]
纪立伟, 纪立农. 新型降糖药钠-葡萄糖共转运蛋白抑制剂的临床疗效 [J]. 中国糖尿病杂志, 2016, 8(4): 253-256.
[9]
Cho NH, Shaw JE, Karuranga S, et al. IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045 [J]. Diabetes Research and Clinical Practice, 2018, 138: 271-281.
[10]
吴光秀, 夏培金, 孙建娟. 达格列净对糖尿病肾病患者肾功能和外周血NLRP3炎性小体表达的影响 [J]. 现代中西医结合杂志, 2020, 29(32): 3551-3554+3627.
[11]
Neal B, Perkovic V, Mahaffey KW, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes [J]. New Engl J Med, 2017, 377(7): 644-657.
[12]
Habibi J, Aroor AR, Sowers JR, et al. Sodium glucose transporter 2 (SGLT2) inhibition with empagliflozin improves cardiac diastolic function in a female rodent model of diabetes [J]. Cardiovasc Diabetol, 2017, 16(1): 9.
[1] 曹雯佳, 刘学兵, 罗安果, 钟释敏, 邓岚, 王玉琳, 李赵欢. 超声矢量血流成像对2型糖尿病患者颈动脉壁剪切应力的研究[J/OL]. 中华医学超声杂志(电子版), 2024, 21(07): 709-717.
[2] 王杰, 袁泉, 王玥琦, 乔佳君, 谭春丽, 夏仲元, 刘守尧. 溃疡油在糖尿病足溃疡治疗中的应用效果及安全性观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 480-484.
[3] 徐志刚, 曹涛, 何亭, 李博奥, 魏婧韬, 张栋梁, 官浩, 杨薛康. 采用抗生素骨水泥治疗糖尿病患者心脏术后胸骨骨髓炎的临床效果观察[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(06): 498-502.
[4] 别瑶, 曹志斌, 辛静, 王健楠, 惠宗光. 应用基质血管成分细胞治疗糖尿病足溃疡的研究进展[J/OL]. 中华损伤与修复杂志(电子版), 2024, 19(05): 453-456.
[5] 孟令凯, 李大勇, 王宁, 王桂明, 张炳南, 李若彤, 潘立峰. 袖状胃切除术对肥胖伴2型糖尿病大鼠的作用及机制研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(06): 638-642.
[6] 李猛, 姜腊, 董磊, 吴情, 贾犇黎. 腹腔镜胃袖状切除术治疗肥胖合并2型糖尿病及脂肪胰的临床研究[J/OL]. 中华普外科手术学杂志(电子版), 2024, 18(05): 554-557.
[7] 严虹霞, 王晓娟, 张毅勋. 2 型糖尿病对结直肠癌患者肿瘤标记物、临床病理及预后的影响[J/OL]. 中华结直肠疾病电子杂志, 2024, 13(06): 483-487.
[8] 周学锋, 董哲毅, 冯哲, 蔡广研, 陈香美. 糖尿病肾脏疾病中西医结合诊疗指南计划书[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 301-305.
[9] 杜军霞, 赵小淋, 王浩然, 高志远, 王曼茜, 万楠熙, 张冬, 丁潇楠, 任琴琴, 段颖洁, 汤力, 朱晗玉. 2 型糖尿病的血液透析患者肠道微生物组学高通量测序分析[J/OL]. 中华肾病研究电子杂志, 2024, 13(06): 313-320.
[10] 杜霞, 马梦青, 曹长春. 造影剂诱导的急性肾损伤的发病机制及干预靶点研究进展[J/OL]. 中华肾病研究电子杂志, 2024, 13(05): 279-282.
[11] 李京, 牛博, 刘晓蓓, 魏新雪, 黄荣. circ-SESN2 沉默靶向调控miRNA-23a-5p/ULK1 在神经细胞氧化应激损伤中的作用机制研究[J/OL]. 中华神经创伤外科电子杂志, 2024, 10(05): 263-272.
[12] 邱岭, 朱旭丽, 浦坚, 邢苗苗, 吴佳玲. 糖尿病肾病患者肠道菌群生态特点与胃肠道功能障碍的关联性研究[J/OL]. 中华消化病与影像杂志(电子版), 2024, 14(05): 453-458.
[13] 张家珺, 张海涛, 苏菲菲. 径向壁应变分析在冠心病诊疗中的应用[J/OL]. 中华临床医师杂志(电子版), 2024, 18(07): 687-691.
[14] 王璇, 娜扎开提·尼加提, 雒洋洋, 蒋升. 皮肤晚期糖基化终末产物浓度与2型糖尿病微血管并发症的相关性[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 447-454.
[15] 王星, 陈园, 热孜万古丽·乌斯曼, 郭艳英. T2DM、Obesity、NASH、PCOS共同致病因素相关的分子机制[J/OL]. 中华临床医师杂志(电子版), 2024, 18(05): 481-490.
阅读次数
全文


摘要